Cargando…
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) in...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409650/ https://www.ncbi.nlm.nih.gov/pubmed/15026795 http://dx.doi.org/10.1038/sj.bjc.6601709 |
_version_ | 1782155822770421760 |
---|---|
author | Geertsen, P F Gore, M E Negrier, S Tourani, J M von der Maase, H |
author_facet | Geertsen, P F Gore, M E Negrier, S Tourani, J M von der Maase, H |
author_sort | Geertsen, P F |
collection | PubMed |
description | A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) infusion (n=103 s.c. and n=225 c.i.v.). No statistically significant differences were found between the cohorts in terms of overall response rate (s.c.: 13.6% vs c.i.v.: 12.4%, P=0.77), response duration (s.c.: 9.8 months vs c.i.v.: 10.1 months, P=0.99), and overall survival (P=0.08). Compared with c.i.v. administration, more patients in the s.c. cohort experienced stable disease (50.5 vs 29.8%) and fewer underwent disease progression (35.0 vs 43.6%). Subcutaneous administration was associated with a significantly lower incidence of grade 3 or 4 adverse events (46 vs 76%; P<0.001), and fewer s.c. patients required dose reductions because of toxicity (20 vs 82%). At the doses and within the schedules tested, this comparative analysis did not detect any difference in efficacy between s.c. and c.i.v. administration of rIL-2 in terms of overall survival, duration of response and response rate in patients with metastatic renal cell carcinoma. However, s.c. delivery of rIL-2 was associated with improved tolerability. |
format | Text |
id | pubmed-2409650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24096502009-09-10 Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma Geertsen, P F Gore, M E Negrier, S Tourani, J M von der Maase, H Br J Cancer Clinical A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) infusion (n=103 s.c. and n=225 c.i.v.). No statistically significant differences were found between the cohorts in terms of overall response rate (s.c.: 13.6% vs c.i.v.: 12.4%, P=0.77), response duration (s.c.: 9.8 months vs c.i.v.: 10.1 months, P=0.99), and overall survival (P=0.08). Compared with c.i.v. administration, more patients in the s.c. cohort experienced stable disease (50.5 vs 29.8%) and fewer underwent disease progression (35.0 vs 43.6%). Subcutaneous administration was associated with a significantly lower incidence of grade 3 or 4 adverse events (46 vs 76%; P<0.001), and fewer s.c. patients required dose reductions because of toxicity (20 vs 82%). At the doses and within the schedules tested, this comparative analysis did not detect any difference in efficacy between s.c. and c.i.v. administration of rIL-2 in terms of overall survival, duration of response and response rate in patients with metastatic renal cell carcinoma. However, s.c. delivery of rIL-2 was associated with improved tolerability. Nature Publishing Group 2004-03-22 2004-03-02 /pmc/articles/PMC2409650/ /pubmed/15026795 http://dx.doi.org/10.1038/sj.bjc.6601709 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Geertsen, P F Gore, M E Negrier, S Tourani, J M von der Maase, H Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma |
title | Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma |
title_full | Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma |
title_fullStr | Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma |
title_full_unstemmed | Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma |
title_short | Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma |
title_sort | safety and efficacy of subcutaneous and continuous intravenous infusion ril-2 in patients with metastatic renal cell carcinoma |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409650/ https://www.ncbi.nlm.nih.gov/pubmed/15026795 http://dx.doi.org/10.1038/sj.bjc.6601709 |
work_keys_str_mv | AT geertsenpf safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma AT goreme safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma AT negriers safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma AT touranijm safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma AT vondermaaseh safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma |